Navigation Links
Watson Announces Actos(R) Patent Challenge Settlement
Date:3/10/2010

MORRISTOWN, N.J., March 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets.  Under terms of the agreement, Takeda granted Watson a non-exclusive royalty free license to its U.S. patents covering Actos®. Under the terms of the agreement, Watson is permitted to launch its generic equivalent version of Actos® on August 17, 2012, or earlier under certain circumstances. 

Actos® had approximately $3.4 billion in brand sales for the twelve months ending December 31, 2009, according to IMS Health. Actos® is a once-daily oral prescription medication that, with diet and exercise, has been shown to be effective for the treatment of type 2 diabetes.

Actos® is a registered trademark of Takeda Chemical Industries, Ltd.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, risks that resolution of patent infringement litigation through settlement could result in investigations or actions by private parties or government authorities, including the U.S. Department of Justice and /or the Federal Trade Commission; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions, if any; availability and pricing of third-party-sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third-party manufacturers' facilities, products, and/or businesses; the impact of competitive products and pricing, market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2009.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)

SOURCE Watson Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.watson.com

'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms Filing of Generic Opana(R) ER Application
2. Watson Signs Agreement to Divest Equity Interest in ScinoPharm
3. Watson to Present at CLSA/Asia USA Investors Forum
4. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
5. Watson Completes Acquisition of Eden Biodesign
6. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
7. Watson Files FDA Application for Generic Rozerem(R)
8. Watson to Present at Credit Suisse Healthcare Conference
9. Watson and Barr Settle Lawsuit Over Oxytrol(R)
10. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
11. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017   FormFast , the ... a new partnership with Engage , one of ... States . FormFast will serve as the forms ... implementations with MEDITECH .  FormFast ... functionality to complement and enhance the electronic health record. ...
(Date:2/16/2017)... Absorption Systems, a global leader in nonclinical ... to announce that its Chief Operating Officer, Sid ... of the 2017 Executive Management Award. The award is ... executives for their creative management vision, leadership philosophy, innovative ... celebration is on March 8, 2017 at the Ballroom ...
(Date:2/16/2017)... 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... today announced that executive management will participate in the ... February 22-23, 2017. Adrian Adams , Chief Executive ... 1:35 p.m. local time on Wednesday, February 22, 2017. ... the event may be accessed from the Investors section ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... ... executives and focusing on all facets of clinical trial planning and management. Pharmica ... patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were able ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses ... Foundation Summit from February 21 - 23 in Beaver Creek, CO. It was announced ... the Summit’s second year in Beaver Creek, hosting over 60 faculty members and addressing ...
(Date:2/16/2017)... ... February 17, 2017 , ... For some cancer survivors, ... final treatments. Physician researchers at The Marcus Institute of Integrative Health at ... efficacy in reducing symptoms of traumatic stress in cancer patients and published ...
(Date:2/16/2017)... ... February 16, 2017 , ... Doctors on Liens is ... to their network through his work at BKP Chiropractic in Lancaster . ... medical degree from Canada’s prestigious International Baccalaureate Program, Dr. Raj went on to ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... ... with the best products in treatment for hair loss, announced today that the ... for over-the-counter (OTC) treatment of hair loss, as well as its clinical-use standing ...
Breaking Medicine News(10 mins):